BioSpace News Archive

GBT Announces New Phase IIa Data at ASH for Voxelotor in Adolescents With Sickle Cell Disease (SCD)

The HOPE-KIDS 1 Study is an ongoing open-label, single- and multiple-dose study evaluating the safety, tolerability, pharmacokinetics and exploratory treatment effect of voxelotor in a pediatric population with SCD.

December 11, 2017

·

8 min read

Drug Development

Intellia Therapeutics Announces New, Robust Genome Editing Data for Sickle Cell Disease at the American Society of Hematology Meeting

Data on ex vivo CRISPR/Cas9 genome-edited human hematopoietic stem cells shows increased production of fetal hemoglobin.

December 11, 2017

·

6 min read

Drug Development

Spark Therapeutics and Pfizer Announce Longer-term Preliminary Data Showing Consistent and Sustained Factor IX Levels in Hemophilia B at 59th American Society of Hematology (ASH) Annual Meeting and Exposition

December 11, 2017

·

10 min read

Drug Development

GBT Announces Presentation of Six Studies at ASH Supporting Voxelotor Sickle Cell Disease (SCD) Program

The data were presented in oral and poster sessions during the 59th American Society of Hematology (ASH) Annual Meeting & Exposition at the Georgia World Congress Center in Atlanta.

December 11, 2017

·

12 min read

Drug Development

Anavex Life Sciences Reports Fiscal 2017 Financial Results And Provides Update On Therapeutic Programs

The Company also provided an update on its most advanced programs for ANAVEX®2-73 for the treatment of Rett syndrome (RTT).

December 11, 2017

·

9 min read

Drug Development

TG Therapeutics Announces Preclinical & Clinical Data Presentations at the 59th American Society of Hematology Annual Meeting

The following summarizes the highlights from each poster presented at the ASH 2017 meeting.

December 11, 2017

·

9 min read

Drug Development

Innovation Pharmaceuticals Reports Positive Topline Results from Phase II Placebo-Controlled Trial of Brilacidin for the Prevention of Oral Mucositis in Head and Neck Cancer Patients

Brilacidin-OM is being developed under an FDA Fast Track designation for this indication.

December 11, 2017

·

10 min read

Genmab’s 2017 R&D Update

Genmab speakers will also discuss the company’s 2017 progress and key goals for 2018.

December 11, 2017

·

4 min read

Drug Development

Actinium Pharmaceuticals Announces Positive Preliminary Results From Phase II Trial for Actimab-A Highlighted at 59th American Society of Hematology Annual Meeting

Actimab-A is the lead candidate from Actinium’s CD33 Program.

December 11, 2017

·

9 min read

Mainstay Medical Announces Positive Outcome of Interim Analysis

Mainstay Medical announces a positive outcome of the Interim Analysis in its U.S. Pivotal ReActiv8-B Study, comprising a definitive size and an estimated completion date.

December 11, 2017

·

4 min read